MBX Biosciences, Inc. today announced positive results from the multiple ascending dose (MAD) portion of the Phase 1 trial of MBX 2109.
Stealth BioTherapeutics Inc. today announced its achievement of target enrollment in the NuPOWER (SPIMD-301) study in patients with primary mitochondrial myopathy (PMM).
Sumitomo Pharma Co., Ltd. companies, Sumitomo Pharma America, Inc. (SMPA) and Sumitomo Pharma Switzerland (SMPS), announced today that the Phase 3 URO-901-3005 clinical study of vibegron.
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA.
Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, today announced the appointment of Philip J. Vickers, Ph.D., as President and Chief Executive Officer.
Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.
AVM Biotechnology, a clinical stage company enrolling Phase 2 adaptive design/expansion cohorts for immunomodulatory AVM0703 in relapsed/refractory Non-Hodgkin Lymphoma/Leukemia patients, will present at the Bio Investor Forum, held in San Francisco, CA October 17-18, 2023.
Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development of novel radiopharmaceuticals.
Sinovac Biotech Ltd. announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
Takeda announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 inhibitor with next generation selectivity, in people with active psoriatic arthritis.
